TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3901875

Group type: EXPERIMENTAL
Intervention: Combination of pirbuterol + theophylline + hydroxyzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pirbuterol + theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ephedrine + theophylline + hydroxyzine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29458404

Group type: EXPERIMENTAL
Intervention: Novel integrated care concept (NICC)
Number of subjects: 2930

Group type: COMPARATOR
Intervention: Standard care (guideline therapy)
Number of subjects: 2930
Study: 27887662

Group type: EXPERIMENTAL
Intervention: Tracheal tube lubricated with water (n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No pretreatment of tracheal tubes (n=150)
Number of subjects: 300
Study: 24561972

Group type: EXPERIMENTAL
Intervention: Multi-component intervention program
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Usual health education curriculum
Number of subjects: 1182
Study: 21831167

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Colesevelam co-administered with oral glucose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20689585

Group type: EXPERIMENTAL
Intervention: amodiaquine/sulfadoxine‐pyrimethamine (AQ/SP)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: artesunate/amodiaquine (AS/AQ)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine (AL)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Insecticide‐treated bednets (ITNs)
Number of subjects: 690
Study: 18514551

Group type: EXPERIMENTAL
Intervention: etoricoxib 30 mg
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: celecoxib 200 mg
Number of subjects: 1207

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1207
Study: 15347630

Group type: EXPERIMENTAL
Intervention: Tendon elongation (TE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postcontraction doublet (PCD) torque
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Electromechanical delay
Number of subjects: 18
Study: 12853536

Group type: EXPERIMENTAL
Intervention: Active limb mobilization plus electrical stimulation (ALM/ES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active limb mobilization (ALM)
Number of subjects: 24
Study: 10385269

Group type: EXPERIMENTAL
Intervention: Ciclosporine A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 0
Study: 8876072

Group type: EXPERIMENTAL
Intervention: 10 mg mizolastine
Number of subjects: 68

Group type: COMPARATOR
Intervention: 10 mg loratadine
Number of subjects: 68
Study: 2065693

Group type: EXPERIMENTAL
Intervention: rolipram
Number of subjects: 50

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 50
Study: 6870319

Group type: EXPERIMENTAL
Intervention: Topically applied tetracycline hydrochloride-containing fluorescent ointments, creams, lotions, and tinctures
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topically applied medications
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vehicle of the topical preparation
Number of subjects: 50
Study: 31785836

Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 30
Study: 31267983

Group type: EXPERIMENTAL
Intervention: Electronic IIEF-5
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Electronic IIEF-15
Number of subjects: 179

Group type: COMPARATOR
Intervention: Paper IIEF-5
Number of subjects: 179

Group type: COMPARATOR
Intervention: Paper IIEF-15
Number of subjects: 179
Study: 27342222

Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 68

Group type: COMPARATOR
Intervention: No salpingectomy
Number of subjects: 68
Study: 26019232

Group type: EXPERIMENTAL
Intervention: APTHotline (telephone assessment of partner(s) plus standard PN)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: APTPharmacy (community pharmacist assessment of partner(s) plus routine PN)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard PN alone (patient referral)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: APTHotline
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: APTPharmacy
Number of subjects: 199
Study: 22820735

Group type: EXPERIMENTAL
Intervention: Pedometer intervention with instructions to log use daily for 6 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pedometer intervention (high adherence group)
Number of subjects: 43
Study: 21669577

Group type: EXPERIMENTAL
Intervention: Diluted propofol (5 mg/mL)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Undiluted propofol (10 mg/mL)
Number of subjects: 86
Study: 19641843

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 74

Group type: COMPARATOR
Intervention: Comparison of hospital-based vs home-based exercise
Number of subjects: 74
Study: 16781073

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg, 1800 mg, 2600 mg (titrated over 4 doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gabapentin (various doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15274172

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day for the first 4 weeks, then flexibly dosed from 10‐20 mg/day)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 315
Study: 11319483

Group type: EXPERIMENTAL
Intervention: Nutrition instruction program for 6 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no nutrition instruction)
Number of subjects: 161
Study: 11233387

Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL, 2.5-5 mg once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enalapril (Enam, 5-10 mg once daily)
Number of subjects: 60
Study: 7838619

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids from menhaden oil (100-131 mg/kg/day, mean 112.8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: n-6 fatty acids from safflower oil (102-132 mg/kg/day, mean 113.3)
Number of subjects: 14
Study: 3078906

Group type: EXPERIMENTAL
Intervention: Once-a-day administration of 1.5 gm of cefatrizine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Twice-a-day administration of 0.75 gm of cefatrizine
Number of subjects: 160
Study: 31170879

Group type: EXPERIMENTAL
Intervention: Self-paced cycling on a desk bike for 45 minutes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 38
Study: 28267471

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 5530

Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 5530
Study: 25946654

Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (20 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Low-dose rosuvastatin (5 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Acute coronary syndrome patients (AMI and UA)
Number of subjects: 123
Study: 24111982

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 21321029

Group type: EXPERIMENTAL
Intervention: 2-year intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4-year intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 19505293

Group type: EXPERIMENTAL
Intervention: Self Determination Theory-based (SDT) exercise on prescription intervention
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard provision exercise on prescription
Number of subjects: 347
Study: 16622120

Group type: EXPERIMENTAL
Intervention: docetaxel/estramustine (D/E)
Number of subjects: 551

Group type: COMPARATOR
Intervention: mitoxantrone/prednisone (M/P)
Number of subjects: 551
Study: 12782457

Group type: EXPERIMENTAL
Intervention: Intervention from Elmira and Memphis Home Visitation sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group from Elmira and Memphis Home Visitation sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teen Parent Welfare Demonstration
Number of subjects: 0

Group type: COMPARATOR
Intervention: New Chance sites
Number of subjects: 0
Study: 10853850

Group type: EXPERIMENTAL
Intervention: Oral ASA challenge (doses 10‐312 mg, cumulative dose 500 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bronchial L‐lysine (L) ASA challenge (doses 0.18‐115 mg, cumulative dose 182 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urinary leukotriene E4 excretion after both challenges
Number of subjects: 50
Study: 9489384

Group type: EXPERIMENTAL
Intervention: Ceftibuten (Cedax) administered once a day for five consecutive days starting on the day of surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: No antibiotic cover (Control group)
Number of subjects: 50
Study: 8360931

Group type: EXPERIMENTAL
Intervention: Beta carotene, vitamin E, and selenium supplementation
Number of subjects: 29584

Group type: COMPARATOR
Intervention: Retinol and zinc supplementation
Number of subjects: 29584

Group type: COMPARATOR
Intervention: Riboflavin and niacin supplementation
Number of subjects: 29584

Group type: COMPARATOR
Intervention: Vitamin C and molybdenum supplementation
Number of subjects: 29584
Study: 2424224

Group type: EXPERIMENTAL
Intervention: Long term plasma exchanges associated with corticosteroids
Number of subjects: 21

Group type: COMPARATOR
Intervention: Corticotherapy alone
Number of subjects: 21
Study: 29768290

Group type: EXPERIMENTAL
Intervention: ARB MED trial (after taking habitual dose of ARB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PLAC trial (after 48 h of placebo medicine)
Number of subjects: 15
Study: 26828000

Group type: EXPERIMENTAL
Intervention: Homeopathic Complex
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: InfluBio
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 23606237

Group type: EXPERIMENTAL
Intervention: Stress condition (social-evaluative threat)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control condition (no social-evaluative threat)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stress and control conditions
Number of subjects: 102
Study: 22713720

Group type: EXPERIMENTAL
Intervention: HPV 16/18 prevalence
Number of subjects: 5002

Group type: EXPERIMENTAL
Intervention: HPV 16 association with CIN3+
Number of subjects: 5002

Group type: EXPERIMENTAL
Intervention: High-grade cervical lesions association
Number of subjects: 5002
Study: 20553564

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) - protein drink without tryptophan
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control - balanced protein drink with tryptophan
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 33
Study: 18441333

Group type: EXPERIMENTAL
Intervention: Raltegravir 1600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study: 16225411

Group type: COMPARATOR
Intervention: Hydroxyethylcellulose (HEC) placebo formulation
Number of subjects: 0
Study: 12507972

Group type: EXPERIMENTAL
Intervention: Vitamin B(6) (40 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitamin B(12) (0.4 mg), folic acid (0.8 mg), and vitamin B(6) (40 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vitamin B(12) and folic acid
Number of subjects: 90
Study: 10910444

Group type: EXPERIMENTAL
Intervention: Carbachol (endothelium-dependent vasodilator)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP; endothelium-independent vasodilator)
Number of subjects: 34
Study: 8880031

Group type: EXPERIMENTAL
Intervention: D-ribose (60 mg.kg-1 injected over 5 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline (control, injected over 5 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: D-ribose and Normal saline (both interventions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: D-ribose
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Circumferential profile analysis (D-ribose vs Normal saline)
Number of subjects: 15
Study: 8518379

Group type: EXPERIMENTAL
Intervention: AV pacing with intervals varied from 0.025 to 0.300 seconds in 0.025-second increments
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AV pacing with optimal intervals between 0.100 and 0.225 seconds
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AV pacing with intervals greater than 0.100 seconds
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AV pacing
Number of subjects: 13
Study: 3307547

Group type: EXPERIMENTAL
Intervention: Zindotrine 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zindotrine 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30709088

Group type: EXPERIMENTAL
Intervention: Hiring more clinical staff
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Increasing frequency of supervisory visits
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Acting on feedback received during supervisory visits
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Financial incentives contingent on specified targets
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: General motivation at work
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Motivation to execute health worker role
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Consequences of high workload
Number of subjects: 94
Study: 28025538

Group type: EXPERIMENTAL
Intervention: IMM beverage intake questionnaire (IMM‐BEVQ)
Number of subjects: 273
Study: 26699169

Group type: EXPERIMENTAL
Intervention: Subcutaneous secukinumab 150 mg
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Subcutaneous secukinumab 75 mg
Number of subjects: 590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study: 23080365

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (10 mg subcutaneously)
Number of subjects: 89
Study: 20202859

Group type: EXPERIMENTAL
Intervention: CVVH treatment (in addition to conventional treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 40
Study: 18215753

Group type: EXPERIMENTAL
Intervention: Brace plus exercise
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ultrasound plus exercise
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy plus exercise
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 16492404

Group type: EXPERIMENTAL
Intervention: Levosimendan (24 microg kg(‐1) bolus plus 24‐h continuous infusion 0.1 microg kg(‐1) min(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dobutamine (initial dose 5 microg kg(‐1) min(‐1), with maximum dose adjustment)
Number of subjects: 22
Study: 12872881

Group type: EXPERIMENTAL
Intervention: Participants instructed to answer yes/no questions randomly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants answering yes/no questions by sensing ostensible keyboard finger movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants answering yes/no questions by sensing unvoiced inclinations
Number of subjects: 0
Study: 10790930

Group type: EXPERIMENTAL
Intervention: Health assessments conducted by non-medical personnel (nurse, lay interviewer/volunteer or office staff)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Health assessments
Number of subjects: 21
Study: 7625467

Group type: EXPERIMENTAL
Intervention: CCK4 (50 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CCK4
Number of subjects: 8
Study: 2575979

Group type: EXPERIMENTAL
Intervention: epanolol 200mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: atenolol 100mg
Number of subjects: 20
Study: 137922

Group type: EXPERIMENTAL
Intervention: Salbutamol, 200 mug
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sch 1000, 40 mug
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of salbutamol (200 mug) and Sch 1000 (40 mug)
Number of subjects: 25
Study: 31937351

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 30218286

Group type: EXPERIMENTAL
Intervention: Probiotic honey (25 g/day containing Bacillus coagulans T11, 108 CFU/g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control honey (25 g/day)
Number of subjects: 60
Study: 28515164

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (FeFol) tablets
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) tablets
Number of subjects: 300

Group type: COMPARATOR
Intervention: Protein energy (PE) as a lipid‐based nutrient supplement (LNS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PE and MMN (PE+MMN) as LNS
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MMN arm
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PE+MMN arm
Number of subjects: 300
Study: 25312998

Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXR screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPST estimates
Number of subjects: 0
Study: 23748441

Group type: EXPERIMENTAL
Intervention: Netupitant alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Palonosetron alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination of netupitant and palonosetron (NEPA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: NEPA with ketoconazole
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: NEPA with rifampicin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: NEPA with ethinylestradiol/levonorgestrel
Number of subjects: 78
Study: 22043466

Group type: EXPERIMENTAL
Intervention: One screw fixation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Two screw fixation
Number of subjects: 12
Study: 19381787

Group type: EXPERIMENTAL
Intervention: Tasks painted black
Number of subjects: 69

Group type: COMPARATOR
Intervention: Tasks striped black and fluorescent lime-green
Number of subjects: 69
Study: 16705487

Group type: EXPERIMENTAL
Intervention: Standardized mistletoe extract (Iscador)
Number of subjects: 0
Study: 14729732

Group type: EXPERIMENTAL
Intervention: Normoxia (N)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoxia (H)
Number of subjects: 10
Study: 11501851

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) starting at 25 microg/hour, titrated to a mean of 87.4 microg/hour by day 56.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with incremental steps of 25 microg/hour.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with immediate release oral morphine (5 mg) every 4-6 hours for the first 12 hours.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with follow-up assessments by palliative care team.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with Karnofsky scale measurements.
Number of subjects: 130
Study: 9232361

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg glucose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg glucose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no glucose)
Number of subjects: 10
Study: 7828515

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 186
Study: 3144542

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Penicillin G 2.4 million units intramuscular plus 1.0 g probenecid orally
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions (Fleroxacin and Penicillin G with Probenecid)
Number of subjects: 80
Study: 31721487

Group type: EXPERIMENTAL
Intervention: Guided-care arm (combinatorial pharmacogenomic testing)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 912
Study: 27465476

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 25403275

Group type: EXPERIMENTAL
Intervention: Motor imagery training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Muscle relaxation
Number of subjects: 44
Study: 23477421

Group type: EXPERIMENTAL
Intervention: 1 × 10^7 piece/mL bone marrow mononuclear cell transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study: 21614411

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18665687

Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 218
Study: 16480406

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg (three pills: one pill twice on the day prior to colonoscopy and one in the morning of colonoscopy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (three pills: one pill twice on the day prior to colonoscopy and one in the morning of colonoscopy)
Number of subjects: 130
Study: 12831624

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 1-2 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous procaine anesthesia (IPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study: 11035344

Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks (highest tertile)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks (middle tertile)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks (lower tertile)
Number of subjects: 36
Study: 8756933

Group type: EXPERIMENTAL
Intervention: Meal consumption (500-kcal mixed-liquid meal)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion (0.3 U/min)
Number of subjects: 18